Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant Enterobacteriaceae Infection|RISS 상세보기

다국어 초록 (Multilingual Abstract)

Background: Infections by Carbapenem-Resistant Enterobacteriaceae (CRE) remain a leading cause of death in critically ill patients. Fosfomycin has been regarded as an alternative therapy for treatment of infections caused by CRE organisms. The purpose of this study is to evaluate clinical outcomes amongst patients with CRE infection who are receiving a fosfomycin dosing regimen using a Monte Carlo simulation and fosfomycin minimum inhibitory concentration (MIC).
Materials and Methods: Fosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation.
Results: In this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/ pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases).
Conclusion: Our findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.

번역하기

참고문헌 (Reference)

1 Prawang A, "Treatment and clinical outcome of Colistin-resistant Klebsiella pneumoniae bacteremia patients" 51 : 263-269, 2020

2 The National Antimicrobial Resistance Surveillance Thailand (NARST), "The situation of antimicrobial resistance in health service areas from January to June 2019"

3 Michalopoulos AS, "The revival of fosfomycin" 15 : e732-e739, 2011

4 Al-aloul M, "The renoprotective effect of concomitant fosfomycin in the treatment of pulmonary exacerbations in cystic fibrosis" 12 : 652-658, 2019

5 Santimaleeworagun W, "The prevalence of colistin-resistant Gram-negative bacteria isolated from hospitalized patients with bacteremia" 10 : 56-59, 2020

6 Tseng SP, "The plasmid-mediated fosfomycin resistance determinants and synergy of fosfomycin and meropenem in carbapenem-resistant Klebsiella pneumoniae isolates in Taiwan" 50 : 653-661, 2017

7 Joukhadar C, "Target site penetration of fosfomycin in critically ill patients" 51 : 1247-1252, 2003

8 Bakthavatchalam YD, "Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence" 6 : FSO461-, 2020

9 Wang J, "Synergistic activity of colistin/fosfomycin combination against carbapenemase-producing Klebsiella pneumoniae in an in vitro pharmacokinetic/pharmacodynamic model" 2018 : 5720417-, 2018

10 Rhodes A, "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016" 43 : 304-377, 2017